Latest

Reliable bioanalysis and regulatory-compliant study design enhance drug development, says Alturas’s Sara Underwood at AAPS PharmSci 360.

The agreement centers on a worldwide, exclusive license to develop and commercialize enzyme replacement therapies using the proprietary platform technology.

At AAPS PharmSci 360, Kelly Donovan says tailored analytical strategies are necessary for reducing development delay risks.

At AAPS PharmSci 360, Ely Porter, PhD, says automated platforms enhance drug production velocity and assay excellence.

At AAPS PharmSci 360 2025, Siddhant Sojitra, Alexion, defines an agitation model to reliably test stability for early-stage biologics.

At AAPS PharmSci 360, Siddhant Sojitra defines a scientifically justified agitation model for the early-stage development of high-concentration biologics.

Financing strategies for new modalities and AI will be central at PharmSci 360, shaping how advanced therapeutics move toward global patient access.

Novel biologics, from ADCs to in-vivo cell therapy, drive AI-enhanced quality control and supply chain flexibility in global biopharma innovation.

A new Cue Biopharma–ImmunoScape partnership seeks to advance targeted TCR-T expansion for solid tumors, supporting broader access and improved clinical durability.

AI, gene therapy, top research breakthroughs, and more will be highlighted at this year’s AAPS PharmSci 360, according to programming chair, Mei He.

As pharmaceutical tariffs reshape costs and global supply chains, it’s essential for industry professionals to be informed about their core impacts and underlying mechanisms.

Digital transformation, data integrity protocols, and regionalized supply chains are crucial strategies for optimizing drug development and manufacturing efficiency, as revealed in our exclusive interviews.

Shilpa Biologicals CEO Sridevi Khambhampaty addresses funding pressures, regional supply strategies, and expanding ADC development.